Sorafenib

Sorafenib. It is an oral multikinase inhibitor developed by the pharmaceutical company Bayer and approved for medical use by regulatory bodies like the Food and Drug Administration and the European Medicines Agency. This targeted therapy is primarily indicated for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and certain cases of thyroid cancer. Its mechanism involves inhibiting several key intracellular and cell surface kinases involved in tumor growth and angiogenesis.

Medical uses

Sorafenib is approved for the treatment of advanced renal cell carcinoma, where it has shown efficacy in improving progression-free survival in clinical trials such as the TARGET trial. It is also a standard systemic therapy for unresectable hepatocellular carcinoma, based on results from the landmark SHARP trial conducted across institutions in Europe and the Americas. Furthermore, the FDA has granted approval for its use in treating locally recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to radioactive iodine, following the positive outcomes of the DECISION trial. Its use is typically guided by oncologists within comprehensive cancer centers like the Memorial Sloan Kettering Cancer Center.

Adverse effects

Common adverse effects associated with sorafenib include hand-foot skin reaction, diarrhea, fatigue, and hypertension, which are often manageable with supportive care. More serious potential complications can involve myocardial infarction, hemorrhage, and gastrointestinal perforation, necessitating careful patient monitoring. The risk of severe skin reactions, such as Stevens-Johnson syndrome, and drug-induced liver injury is also noted in post-marketing surveillance by agencies like the FDA. Management strategies are frequently discussed in forums like the American Society of Clinical Oncology annual meetings.

Pharmacology

Sorafenib functions as a small molecule inhibitor that targets several tyrosine kinases, including VEGFR, PDGFR, and RAF kinase, which are pivotal in tumor cell proliferation and angiogenesis. It is metabolized primarily in the liver via oxidative metabolism mediated by the cytochrome P450 system, specifically CYP3A4, and is also a substrate for UGT1A9. The drug achieves peak plasma concentrations approximately three hours after oral administration and has a half-life of about 25 to 48 hours. Its pharmacokinetics can be influenced by concomitant use of strong inducers or inhibitors of CYP3A4, such as rifampin or ketoconazole.

History

The discovery and development of sorafenib originated from collaborative research between Bayer and Onyx Pharmaceuticals in the late 1990s. It received its first regulatory approval from the FDA in 2005 for advanced renal cell carcinoma, marking a significant advancement in targeted cancer therapy. Subsequent approvals followed for hepatocellular carcinoma in 2007 and for thyroid cancer in 2013, based on pivotal phase III trials. The drug's development history is often cited in publications like the New England Journal of Medicine and has been recognized with awards from organizations such as the American Association for Cancer Research.

Society and culture

Marketed under the brand name Nexavar, sorafenib has been the subject of significant discussion regarding its high cost and accessibility in healthcare systems worldwide, including debates within the National Health Service in the United Kingdom. It is listed on the World Health Organization Model List of Essential Medicines, highlighting its importance in global oncology. The drug has also been involved in legal and patent disputes in various jurisdictions, including cases heard by the Supreme Court of the United States. Its impact is frequently analyzed in health economics studies presented at conferences like those of the International Society for Pharmacoeconomics and Outcomes Research.

Category:Antineoplastic drugs Category:Bayer brands Category:Multikinase inhibitors